Skin Tech’s Award-Winning Injectable Forges New ‘Skin Builder’ Category

BARCELONA, Spain – June 17, 2026 – In a move that validates a significant shift in the multi-billion-dollar aesthetic medicine industry, Skin Tech Pharma Group has secured a major accolade for its flagship injectable, RRS® HA Long Lasting. The product was named 'Best Injectable in Skin Revitalization' at the 2026 AMWC Aesthetic Medicine Awards, a highly prestigious event considered a benchmark for innovation and excellence in the global aesthetics community.

While the award itself is a notable achievement, its strategic implication runs deeper. It provides a global stage for what the company is championing as an entirely new class of treatment: the 'Skin Builder.' This win is not just a product endorsement; it’s a strategic maneuver to define and lead a new market category that bridges the gap between existing solutions, reflecting a profound change in how both practitioners and patients approach skin aging.

Beyond Fillers: The Strategic Rise of the 'Skin Builder'

For years, the injectable market has been largely bifurcated. Dermal fillers, typically made of cross-linked hyaluronic acid, focus on restoring lost volume and sculpting facial contours. At the other end, skin boosters offer superficial hydration and a temporary glow, improving skin texture without providing structural support. Skin Tech Pharma Group is positioning RRS® HA Long Lasting to transcend this dichotomy. The company explicitly states the product is “neither a skin booster nor a dermal filler,” but rather a hybrid that “combines the most valued characteristics of both.”

This new 'Skin Builder' category is defined by a dual-action approach. The product’s formulation features cross-linked hyaluronic acid, providing the subtle lift and structural support reminiscent of a soft filler. However, it is combined with a protective buffer of 15 amino acids, the essential building blocks for proteins like collagen and elastin. This combination is engineered to do more than just fill; it aims to revitalize the dermal environment, improve skin quality from within, and promote long-term skin health. This aligns with a growing industry trend toward “hybrid injectables” that offer both immediate aesthetic improvement and progressive, regenerative benefits.

According to the company, this allows patients to see an immediate, natural-looking enhancement while also benefiting from progressive improvements in skin texture, firmness, and elasticity in the weeks following treatment. The success of this approach is backed by significant market adoption, with the company reporting over one million treatments performed worldwide since the product's 2021 launch.

A Milestone Built on 30 Years of Innovation

This award serves as a capstone for Skin Tech Pharma Group as it celebrates its 30th anniversary. Founded in 1994 by Dr. Philippe Deprez, the Spanish company has a history of pioneering new treatments, notably establishing itself with the launch of the Easy TCA® chemical peel in 1996. The recent win for RRS® HA Long Lasting is presented as the culmination of a deliberate, long-term vision.

“Receiving this award is an important milestone for us and a testament to the strength of our long-term strategy,” said Márcio Rodrigues, CEO of Skin Tech Pharma Group, in a statement. “As the aesthetic medicine landscape continues to evolve, our ambition is to lead through scientific rigor, differentiated innovation, and a deep understanding of healthcare professionals' needs.”

This strategic focus is further underscored by the company’s ownership structure. Backed by private equity firms Charterhouse Capital Partners and EXCELSIS, Skin Tech Pharma Group is positioned for aggressive growth and market leadership. The investment from such firms signals a belief in the company’s potential to not only compete but to redefine market segments. The emphasis on scientific rigor, with a global R&D team and an in-house laboratory, provides the foundation for creating and validating novel product categories like the 'Skin Builder.'

Validating a Shift Towards Regenerative Aesthetics

The recognition from the AMWC is particularly significant. The World Congress, which draws over 15,000 professionals, is a critical forum where industry trends are solidified. An award, judged by a panel of experts and voted on by peers, lends powerful third-party validation to a company’s claims. It elevates the 'Skin Builder' concept from a marketing term to an award-winning, industry-recognized category.

This success taps directly into the dominant consumer demand for more natural-looking results and treatments that support graceful aging. The modern patient is increasingly seeking enhancements that are not immediately obvious, focusing on skin health and vitality over dramatic alteration. The regenerative promise of the 'Skin Builder'—improving the skin’s own structure and function—is perfectly aligned with this ethos.

Dr. Javed Hussain, a Key Opinion Leader for the company, highlighted the clinical performance. "Clinical use has demonstrated consistent improvements in skin texture, elasticity, and overall luminosity," he noted, attributing the results to the unique combination of hyaluronic acid and the amino acid buffer. He added that the formulation provides “essential components required for restoration of natural dermal function,” delivering reproducible outcomes with a high safety profile.

Carving a Niche in a Competitive Landscape

The injectable aesthetics market is intensely competitive, with established giants and nimble innovators vying for market share. Recent AMWC awards in similar categories have gone to formidable products like Juvelook and FILLMED's NCTF® 135 HA, highlighting the high bar for innovation. In this crowded field, Skin Tech Pharma Group’s strategy is not to compete on the same terms, but to create a new game.

By defining and championing the 'Skin Builder' category, the company is attempting to carve out a unique space where it is the incumbent leader. This move shifts the conversation from a direct comparison of specifications to a discussion of a novel treatment philosophy. The AMWC award provides the critical momentum needed for this strategy to succeed, lending it credibility among the practitioners who will ultimately drive adoption. As the industry continues its evolution toward holistic and regenerative solutions, this award-winning approach positions Skin Tech Pharma Group at the forefront of the market’s next chapter.